Loading...
XNASDCTH
Market cap406mUSD
Jan 15, Last price  
12.71USD
1D
0.16%
1Q
24.24%
Jan 2017
-100.00%
Name

Delcath Systems Inc

Chart & Performance

D1W1MN
XNAS:DCTH chart
P/E
—
P/S
196.80
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
235.55%
Rev. gr., 5y
-9.53%
Revenues
2m
-24.05%
00000000346,000790,0001,069,0001,747,0001,992,0002,715,0003,407,0001,580,0001,646,0003,555,0002,719,0002,065,000
Net income
-48m
L+21.74%
-3,266,332-2,864,619-10,951,605-3,663,506-6,864,885-22,056,592-46,683,645-30,885,000-51,868,000-30,324,000-17,381,000-14,704,000-17,971,000-45,117,000-19,222,000-13,627,000-24,485,000-26,757,000-39,163,000-47,678,000
CFO
-31m
L+25.25%
-2,946,086-3,019,217-9,202,451-5,569,197-6,723,277-10,462,242-24,082,714-37,372,000-50,006,000-34,102,000-15,552,000-16,420,000-14,213,000-15,398,000-14,732,000-23,690,000-22,868,000-22,604,000-24,950,000-31,251,000
Earnings
Mar 24, 2025

Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
URL
https://delcath.com/
IPO date
Oct 19, 2000
Employees
52
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,065
-24.05%
2,719
-23.52%
Cost of revenue
18,137
19,269
Unusual Expense (Income)
NOPBT
(16,072)
(16,550)
NOPBT Margin
Operating Taxes
2,655
Tax Rate
NOPAT
(16,072)
(19,205)
Net income
(47,678)
21.74%
(39,163)
46.37%
Dividends
Dividend yield
Proceeds from repurchase of equity
23,083
10,857
BB yield
-34.19%
-34.02%
Debt
Debt current
10,224
8,032
Long-term debt
37
8,028
Deferred revenue
Other long-term liabilities
6,388
1,144
Net debt
(22,193)
8,389
Cash flow
Cash from operating activities
(31,251)
(24,950)
CAPEX
(58)
(209)
Cash from investing activities
(19,709)
(209)
Cash from financing activities
51,778
10,143
FCF
(15,820)
(18,940)
Balance
Cash
32,454
7,671
Long term investments
Excess cash
32,351
7,535
Stockholders' equity
(504,799)
(457,467)
Invested Capital
537,188
468,626
ROIC
ROCE
EV
Common stock shares outstanding
16,230
8,865
Price
4.16
15.56%
3.60
-53.55%
Market cap
67,517
111.57%
31,913
-42.37%
EV
45,324
40,302
EBITDA
(15,944)
(16,418)
EV/EBITDA
Interest
1,439
2,685
Interest/NOPBT